PCI Biotech: Unveiling Promising Results in 2024

PCI Biotech (OSE: PCIB), a Norwegian biopharmaceutical company specializing in photochemical technologies, has invited investors and stakeholders to its preliminary full-year 2024 results presentation. The event, scheduled for Thursday, February 27, 2025, at 08:30 am – 09:00 am CET, will provide valuable insights into the company's operational and financial performance during the year.



PCI Biotech's core technologies, Photochemical Internalisation (PCI) and Photochemical Lysis (PCL), have shown promising results in various applications, including viral vector manufacturing, intratumoural immunotherapy, and site-directed intracellular nucleic acid delivery. The company's focus on enhancing yield and purity in viral vector manufacturing, as well as unlocking the potential of diverse therapeutic modalities, positions it well in the competitive biotech landscape.

In the first half of 2024, PCI Biotech reported a cash position of NOK 30.5 million, which is expected to support operations into the second half of 2025 under current strategic plans. This financial flexibility provides an opportunity window for the company to demonstrate the commercial potential of its technology platform.

Ronny Skuggedal, CEO of PCI Biotech, commented on the positive trajectory of the company: "Upon receiving encouraging feedback from early field testing at the start of this year, we propelled our development efforts further by successfully advancing the PCL technology to a renowned service provider for scale-up applications. The results from the initial mini benchtop bioreactor trials have provided vital insights into the technology’s compatibility with standard manufacturing processes, which is a crucial factor in our ongoing business development conversations."



PCI Biotech's clinical pipeline consists of three distinct anticancer paradigms: fimaChem, fimaVacc, and fimaNAc. The company's lead program, fimaChem, consists of a pivotal study in bile duct cancer, an orphan indication with a high unmet need and without approved products. The company's interactions with regulatory authorities in the US (FDA) and Europe (EMA) regarding a modified study design for the RELEASE study have provided valuable insights into the potential challenges and opportunities in the development process.

In conclusion, PCI Biotech's invitation to its preliminary full-year 2024 results presentation offers investors and stakeholders an opportunity to gain insights into the company's progress and future prospects. With promising results in its photochemical technologies, a strong cash position, and a robust clinical pipeline, PCI Biotech is well-positioned to continue its growth trajectory in the biotech industry.